Avanzini P - Search Results

1

Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. A report from the Italian Lymphoma Study Group (GISL).

Federico M, Gobbi PG, Moretti G, Avanzini P, Di Renzo N, Cavanna L, Ascari E, Silingardi V. Federico M, et al. Among authors: avanzini p. Am J Clin Oncol. 1995 Feb;18(1):8-14. doi: 10.1097/00000421-199502000-00002. Am J Clin Oncol. 1995. PMID: 7847265 Clinical Trial.

2

ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.

Federico M, Moretti G, Gobbi PG, Avanzini P, Cavanna L, Carotenuto M, Lombardo M, Leone G, Pitini V, Abbadessa V, et al. Federico M, et al. Among authors: avanzini p. Leukemia. 1991;5 Suppl 1:95-101. Leukemia. 1991. PMID: 1716340 Clinical Trial.

3

MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.

Gobbi PG, Pieresca C, Federico M, Di Renzo N, Narni F, Iannitto E, Grignani G, Cavanna L, Avanzini P, Partesotti G, et al. Gobbi PG, et al. Among authors: avanzini p. J Clin Oncol. 1993 Apr;11(4):712-9. doi: 10.1200/JCO.1993.11.4.712. J Clin Oncol. 1993. PMID: 7683044

4

ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).

Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. Silingardi V, et al. Among authors: avanzini p. Leuk Lymphoma. 1995 Apr;17(3-4):313-20. doi: 10.3109/10428199509056837. Leuk Lymphoma. 1995. PMID: 8580801 Clinical Trial.

5

Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.

Gobbi PG, Pieresca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A, Berté R, Avanzini P, Federico M, Silingardi V, Ascari E. Gobbi PG, et al. Among authors: avanzini p. J Clin Oncol. 1996 Feb;14(2):527-33. doi: 10.1200/JCO.1996.14.2.527. J Clin Oncol. 1996. PMID: 8636767 Clinical Trial.

6

A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.

Baldini L, Guffanti A, Gobbi P, Colombi M, Federico M, Avanzini P, Cavanna L, Pieresca C, Silingardi V, Maiolo AT. Baldini L, et al. Among authors: avanzini p. Cancer. 1997 Mar 15;79(6):1234-40. doi: 10.1002/(sici)1097-0142(19970315)79:6<1234::aid-cncr24>3.0.co;2-#. Cancer. 1997. PMID: 9070503

7

Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.

Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V. Federico M, et al. Among authors: avanzini p. Haematologica. 1998 Sep;83(9):800-11. Haematologica. 1998. PMID: 9825577 Free article. Clinical Trial.

8

A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).

Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E. Gobbi PG, et al. Among authors: avanzini p. Haematologica. 2000 Mar;85(3):263-8. Haematologica. 2000. PMID: 10702814

9

Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.

Brugiatelli M, Federico M, Gobbi PG, Avanzini P, Callea V, Cavanna L, De Pasquale A, Di Prisco AU, Di Rienzo N, Silingardi V, et al. Brugiatelli M, et al. Among authors: avanzini p. Haematologica. 1993 Sep-Oct;78(5):306-12. Haematologica. 1993. PMID: 8314160 Free article. Clinical Trial.

10

Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres.

Longo G, Federico M, Pieresca C, Avanzini P, Iannitto E, Di Prisco AU, Baldini L, Brugiatelli M, Clò V, Bevini M, et al. Longo G, et al. Among authors: avanzini p. Eur J Cancer. 1995 Oct;31A(11):1763-7. doi: 10.1016/0959-8049(95)00318-d. Eur J Cancer. 1995. PMID: 8541096 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters